First, it's a highly ranked journal, so good impact. Also, note the JCO authors analysis is on an ITT basis and OS difference is higher than of the ASCO abs.: ASCO - Median TTP: 28 vs. 11 wks (p=0.012) and OS: 18 vs. 11 mos (p=0.0136). JCO - Median TTP: 27.5 vs. 10.1 wks (P< .001) and OS: 17.7 vs. 7.6 mos (p= .0052) Patients who failed 5FU have usually poor RR to later treatment line, there were 25 of them in this trial and the stat-sig increase in OS and TTP in this subgroup is important, imo.
The two arms were quite balanced, see in the ASCO abs.